Drug Profile
Mirodenafil - AriBio
Alternative Names: AR-1001Latest Information Update: 02 May 2024
Price :
$50
*
At a glance
- Originator AriBio
- Class Anxiolytics; Erectile dysfunction therapies; Piperazines; Pyrimidinones; Small molecules; Sulfones
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease
- Phase I Dementia; Lewy body disease; Post-traumatic stress disorders; Stroke
- Preclinical Parkinson's disease
Most Recent Events
- 02 May 2024 AriBio plans a phase III POLARIS-AD trial for Alzheimer's disease (Early stage disease) in Czech Republic, Denmark, France, Germany, Italy, Spain and the Netherlands (PO, Tablet) in Q2 of 2024
- 24 Apr 2024 EMA approves clinical trial authorization application for mirodenafil in Alzheimer's disease
- 24 Mar 2024 AriBio licenses exclusive marketing rights of Mirodenafil to an Unknown company in China for Alzheimer’s disease